Deutsch English Français

Contact

EP2949335

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP2949335

EP2949335 - LOW FREQUENCY GLATIRAMER ACETATE THERAPY [Right-click to bookmark this link]
Status	Patent revoked Status updated on 27.04.2021 Database last updated on 11.04.2026
Former	The patent has been granted Status updated on 02.12.2016
Former	Grant of patent is intended Status updated on 30.11.2016
Most recent event Tooltip	30.04.2021	Revocation of patent	published on 02.06.2021 [2021/22]
Applicant(s)	For all designated states YEDA RESEARCH & DEVELOPMENT COMPANY, LTD. P.O. Box 95 76100 Rehovot / IL
	[2015/49]
Inventor(s)	01 / Klinger, Ety 16 Agadati Street 39930 Tel Aviv / IL
	[2015/49]
Representative(s)	D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB
	[N/P]
Former [2015/49]	D Young & Co LLP 120 Holborn London EC1N 2DY / GB
Application number, filing date	15171065.4	19.08.2010
	[2015/49]
Priority number, date	US20090274687P	20.08.2009 Original published format: US 274687 P
	US20100337612P	11.02.2010 Original published format: US 337612 P
	[2015/49]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP2949335
	Date:	02.12.2015
	Language:	EN
	[2015/49]
	Type:	B1 Patent specification
	No.:	EP2949335
	Date:	04.01.2017
	Language:	EN
	[2017/01]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	16.10.2015
Classification	IPC:	A61K38/02, A61K38/16, A61P25/28, A61K38/07, A61K9/00, A61K31/785	[2016/43]
	CPC:	A61K31/19 (EP,US); A61K38/02 (EP,AT,US); A61K31/195 (KR); A61K38/16 (AT,CN,EA,US); A61K31/198 (EA); A61K9/0019 (AT,CN,US); (+) A61K31/785 (EP,US); A61K38/07 (US); A61K47/26 (CN); A61K9/08 (KR); A61P25/00 (EA); A61P3/10 (EP,US) (-)
	Former IPC [2015/49]	A61K38/02, A61K38/16, A61P25/28, A61K38/07, A61K9/00
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2015/49]
Extension states	BA	08.06.2015
	ME	08.06.2015
	RS	08.06.2015
Title	German:	NIEDRIGFREQUENTE GLATIRAMERAZETATTHERAPIE	[2015/49]
	English:	LOW FREQUENCY GLATIRAMER ACETATE THERAPY	[2015/49]
	French:	THÉRAPIE À L'ACÉTATE DE GLATIRAMÈRE À BASSE FRÉQUENCE	[2015/49]
Examination procedure	08.06.2015	Examination requested [2015/49]
	21.01.2016	Despatch of a communication from the examining division (Time limit: M04)
	23.05.2016	Reply to a communication from the examining division
	19.08.2016	Despatch of a communication from the examining division (Time limit: M01)
	20.08.2016	Reply to a communication from the examining division
	27.10.2016	Communication of intention to grant the patent
	28.11.2016	Fee for grant paid
	28.11.2016	Fee for publishing/printing paid
	28.11.2016	Receipt of the translation of the claim(s)
	06.12.2016	Observations by third parties
Parent application(s) Tooltip	EP10810282.3 / EP2405749
	EP13166080.5 / EP2630962
Opposition(s)	Opponent(s)	01 03.10.2017 09.10.2017 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4, Trident Place Mosquito Way, Hatfield GB-Hertfordshire AL 10 9UL / GB Opponent's representative Gill Jennings & Every LLP, et al, et al The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
		02 04.10.2017 09.10.2017 ADMISSIBLE Synthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 04.10.2017 13.10.2017 ADMISSIBLE Alvogen IPCo S.a.r.l. 5 rue Heienhaff 1736 Senningerberg / LU Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		04 04.10.2017 13.10.2017 ADMISSIBLE G. L. Pharma GmbH Schlossplatz 1 8502 Lannach / AT Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		05 04.10.2017 13.10.2017 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Breuer, Markus, et al, et al Sendlinger Straße 29 80331 München / DE
		06 27.11.2017 27.11.2017 INTERVENTION ADMISSIBLE Mylan Teoranta Trading as Mylan Institutional Inverin H91 Co. Galway / IE Opponent's representative Gill Jennings & Every LLP The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
		[N/P]
	Former [2021/20]
	Opponent(s)	01 03.10.2017 09.10.2017 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4, Trident Place Mosquito Way, Hatfield GB-Hertfordshire AL 10 9UL / GB Opponent's representative Gill Jennings & Every LLP, et al, et al MXL The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
		02 04.10.2017 09.10.2017 ADMISSIBLE Synthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 04.10.2017 13.10.2017 ADMISSIBLE Alvogen IPCo S.a.r.l. 5 rue Heienhaff 1736 Senningerberg / LU Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		04 04.10.2017 13.10.2017 ADMISSIBLE G. L. Pharma GmbH Schlossplatz 1 8502 Lannach / AT Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		05 04.10.2017 13.10.2017 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Breuer, Markus, et al, et al Brienner Straße 1 80333 München / DE
		06 27.11.2017 27.11.2017 INTERVENTION ADMISSIBLE Mylan Teoranta Trading as Mylan Institutional Inverin H91 Co. Galway / IE Opponent's representative Gill Jennings & Every LLP APC The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
	Former [2020/18]
	Opponent(s)	01 03.10.2017 09.10.2017 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4, Trident Place Mosquito Way, Hatfield GB-Hertfordshire AL 10 9UL / GB Opponent's representative Gill Jennings & Every LLP, et al, et al MXL The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
		02 04.10.2017 09.10.2017 ADMISSIBLE Synthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 04.10.2017 13.10.2017 ADMISSIBLE Alvogen IPCo S.a.r.l. 5 rue Heienhaff 1736 Senningerberg / LU Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		04 04.10.2017 13.10.2017 ADMISSIBLE G. L. Pharma GmbH Schlossplatz 1 8502 Lannach / AT Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		05 04.10.2017 13.10.2017 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Breuer, Markus, et al, et al Brienner Straße 1 80333 München / DE
		06 27.11.2017 27.11.2017 INTERVENTION ADMISSIBLE Mylan Teoranta Trading as Mylan Institutional Inverin H91 Co. Galway / IE Opponent's representative Gill Jennings & Every LLP APC The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
	Former [2019/45]
	Opponent(s)	01 03.10.2017 09.10.2017 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4, Trident Place Mosquito Way, Hatfield GB-Hertfordshire AL 10 9UL / GB Opponent's representative Gill Jennings & Every LLP, et al, et al MXL The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
		02 04.10.2017 09.10.2017 ADMISSIBLE Synthon B.V./Genthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 04.10.2017 13.10.2017 ADMISSIBLE Alvogen IPCo S.a.r.l. 5 rue Heienhaff 1736 Senningerberg / LU Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		04 04.10.2017 13.10.2017 ADMISSIBLE G. L. Pharma GmbH Schlossplatz 1 8502 Lannach / AT Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		05 04.10.2017 13.10.2017 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Breuer, Markus, et al, et al Brienner Straße 1 80333 München / DE
		06 27.11.2017 27.11.2017 INTERVENTION ADMISSIBLE Mylan Teoranta Trading as Mylan Institutional Inverin H91 Co. Galway / IE Opponent's representative Gill Jennings & Every LLP APC The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
	Former [2018/08]
	Opponent(s)	01 03.10.2017 09.10.2017 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4, Trident Place Mosquito Way, Hatfield GB-Hertfordshire AL 10 9UL / GB Opponent's representative Gill Jennings & Every LLP, et al, et al MXL The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
		02 04.10.2017 09.10.2017 ADMISSIBLE Synthon B.V./Genthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 04.10.2017 13.10.2017 ADMISSIBLE Alvogen IPCo S.a.r.l. 5 rue Heienhaff 1736 Senningerberg / LU Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		04 04.10.2017 13.10.2017 ADMISSIBLE G. L. Pharma GmbH Schlossplatz 1 8502 Lannach / AT Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		05 04.10.2017 13.10.2017 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner, et al, et al Patentanwälte Brienner Strasse 1 80333 München / DE
		06 27.11.2017 27.11.2017 INTERVENTION ADMISSIBLE Mylan Teoranta Trading as Mylan Institutional Inverin H91 Co. Galway / IE Opponent's representative Gill Jennings & Every LLP APC The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
	Former [2018/01]
	Opponent(s)	01 03.10.2017 09.10.2017 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4, Trident Place Mosquito Way, Hatfield GB-Hertfordshire AL 10 9UL / GB Opponent's representative Gill Jennings & Every LLP, et al, et al MXL The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
		02 04.10.2017 09.10.2017 ADMISSIBLE Synthon B.V./Genthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 04.10.2017 13.10.2017 ADMISSIBLE Alvogen IPCo S.a.r.l. 5 rue Heienhaff 1736 Senningerberg / LU Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		04 04.10.2017 13.10.2017 ADMISSIBLE G. L. Pharma GmbH Schlossplatz 1 8502 Lannach / AT Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		05 04.10.2017 13.10.2017 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner, et al, et al Patentanwälte Brienner Strasse 1 80333 München / DE
		06 27.11.2017 INTERVENTION ADMISSIBLE Mylan Teoranta Trading as Mylan Institutional Inverin H91 Co. Galway / IE Opponent's representative Gill Jennings & Every LLP APC The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
	Former [2017/47]
	Opponent(s)	01 03.10.2017 09.10.2017 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4, Trident Place Mosquito Way, Hatfield GB-Hertfordshire AL 10 9UL / GB Opponent's representative Gill Jennings & Every LLP, et al, et al MXL The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
		02 04.10.2017 09.10.2017 ADMISSIBLE Synthon B.V./Genthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 04.10.2017 13.10.2017 ADMISSIBLE Alvogen IPCo S.a.r.l. 5 rue Heienhaff 1736 Senningerberg / LU Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		04 04.10.2017 13.10.2017 ADMISSIBLE G. L. Pharma GmbH Schlossplatz 1 8502 Lannach / AT Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		05 04.10.2017 13.10.2017 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner, et al, et al Patentanwälte Brienner Strasse 1 80333 München / DE
	Former [2017/46]
	Opponent(s)	01 03.10.2017 09.10.2017 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4, Trident Place Mosquito Way, Hatfield GB-Hertfordshire AL 10 9UL / GB Opponent's representative Gill Jennings & Every LLP, et al, et al MXL The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
		02 04.10.2017 09.10.2017 ADMISSIBLE Synthon B.V./Genthon B.V. Microweg 22 6545 CM Nijmegen / NL Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		03 04.10.2017 ADMISSIBLE Alvogen IPCo S.a.r.l. 5 rue Heienhaff 1736 Senningerberg / LU Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		04 04.10.2017 ADMISSIBLE G. L. Pharma GmbH Schlossplatz 1 8502 Lannach / AT Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB, et al, et al Jungfernstieg 38 20354 Hamburg / DE
		05 04.10.2017 Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Henkel, Breuer & Partner, et al, et al Patentanwälte Erika-Mann Strasse 23 80636 München / DE
	09.11.2017	Invitation to proprietor to file observations on the notice of opposition
	18.05.2018	Reply of patent proprietor to notice(s) of opposition
	28.03.2019	Date of oral proceedings
	13.05.2019	Despatch of interlocutory decision in opposition
	13.05.2019	Despatch of minutes of oral proceedings
	10.09.2020	Legal effect of revocation of patent [2021/22]
	31.03.2021	Despatch of communication that the patent will be revoked
Appeal following opposition	04.07.2019	Appeal received No. T1343/19
	23.09.2019	Statement of grounds filed
	10.09.2020	Result of appeal procedure: revocation of the patent
	31.03.2021	Despatch of the decision of the Board of Appeal
	02.04.2019	Appeal received No. T1343/19
	11.09.2019	Statement of grounds filed
	10.09.2020	Result of appeal procedure: revocation of the patent
	31.03.2021	Despatch of the decision of the Board of Appeal
	05.04.2019	Appeal received No. T1343/19
	02.09.2019	Statement of grounds filed
	10.09.2020	Result of appeal procedure: revocation of the patent
	31.03.2021	Despatch of the decision of the Board of Appeal
	10.09.2020	Date of oral proceedings
Fees paid	Renewal fee
	08.06.2015	Renewal fee patent year 03
	08.06.2015	Renewal fee patent year 04
	08.06.2015	Renewal fee patent year 05
	08.06.2015	Renewal fee patent year 06
	22.08.2016	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	NL	04.01.2017
	GB	21.11.2017
	[2018/21]
Former [2017/40]	NL	04.01.2017
Documents cited:	Search	[I] US2007161566 (PINCHASI IRIT et al.)
		[A] FLECHTER S ET AL: "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 197, no. 1-2, 15 May 2002 (2002-05-15), pages 51 - 55, XP002679780, ISSN: 0022-510X DOI: http://dx.doi.org/10.1016/S0022-510X(02)00047-3
		[A] FLECHTER SHLOMO ET AL: "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.", CLINICAL NEUROPHARMACOLOGY 2002 JAN-FEB LNKD- PUBMED:11852290, vol. 25, no. 1, January 2002 (2002-01-01), pages 11 - 15, XP009161076, ISSN: 0362-5664 DOI: http://dx.doi.org/10.1097/00002826-200201000-00002
		[A] KHAN O ET AL: "Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every - other - day injections in relapsing -remitting multiple", MULT.SCLER. (14, SUPPL. 1, S296, 2008) 0 REF. ISSN: 1352-4585 AV - WAYNE STATE UNIV, SCH MED, DETROIT, MI, USA., P902, 2008, XP009161078
		[A] CAON CHRISTINA ET AL: "Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", NEUROLOGY, vol. 72, no. 11, Suppl. 3, March 2009 (2009-03-01), & 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA; APRIL 28 -29, 2009, pages A317, XP009161100, ISSN: 0028-3878
		[I] COHEN J A ET AL: "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.", NEUROLOGY 20 MAR 2007 LNKD- PUBMED:17372130, vol. 68, no. 12, 20 March 2007 (2007-03-20), pages 939 - 944, XP002679784, ISSN: 1526-632X DOI: http://dx.doi.org/10.1212/01.wnl.0000257109.61671.06
		[A] SIMPSON DENE ET AL: "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis.", CNS DRUGS, vol. 16, no. 12, 2002, pages 825 - 850, XP009161077, ISSN: 1172-7047 DOI: http://dx.doi.org/10.2165/00023210-200216120-00004
		[I] ANONYMOUS: "Teva Provides Update on FORTE Trial", 7 July 2008 (2008-07-07), XP002743817, Retrieved from the Internet [retrieved on 20150831]
		[I] YONG WEE V ET AL: "Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial", NEUROLOGY, vol. 72, no. 11, Suppl. 3, March 2009 (2009-03-01), & 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA; APRIL 28 -29, 2009, pages A39, XP002743818, ISSN: 0028-3878
	by applicant	US2002055466
		US2005014694
		US2002077278
		US2003004099
		US2002037848
		US6514938
		WO0160392
		WO0027417
		WO0197846
		US2008013146
		WO2009070298
		US2009149541
		G. COMI ET AL.: "European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetere on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients with Relapsing Multiple Sclerosis", ANN. NEUROL., vol. 49, 2001, pages 290 - 297, XP009042363, DOI: doi:10.1002/ana.64 DOI: http://dx.doi.org/10.1002/ana.64
		POSER ET AL., NEUROLOGY, vol. 13, no. 3, March 1983 (1983-03-01), pages 227 - 230
		ANN NEUROL, vol. 58, 2005, pages 840 - 846
		KANSARA V; MITRA A; WU Y: "Subcutaneous Delivery", DRUG DELIV TECHNOL, vol. 9, no. 6, June 2009 (2009-06-01), pages 38 - 42
		LUCA DURELLI, J NEUROL, no. 4, 2003, pages 250
	other	US8969302
		US8399413
		EP2405749
		Y.-C. J. WANG: "PARENTERAL FORMULATIONS OF PROTEINS AND PEPTIDES: STABILITY AND STABILIZERS", J. PARENT. SCI. TECHN., vol. 42, no. 2S, 1988, pages S4 - S26, XP000984636
	Opposition	WO2007081975
		US27468772
		WO2011022063
		WO2011022063
		US2007161566
		US27468709
		EP2949335
		WO0020010
		WO2011022063
		US2007161566
		US27468709
		EP2949335
		WO0020010
		"View of NCT01067521", CLINICALTRIALS.GOV ARCHIVE, 10 February 2010 (2010-02-10), XP055508500
		"FDA label Rebif PI", WWW.ACCESSDATA.FDA.GOV, 8 March 2002 (2002-03-08), XP055508530, Retrieved from the Internet
		J.J JESSOP: "Review and Evaluation of Pharmacology Toxicology Data", ORIGINAL NDA REVIEW, NDA 20-622, COPOLYMER-1 FOR TREATMENT OF RELAPS- ING-REMITTING MULTIPLE SCLEROSIS, 1996, XP055508552
		GRENNERO ALFONSO: "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY, Easton, Pennsylvania, pages: 1813 - 1827, XP055508569
		KHAN O. ET AL.: "Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every-other-day glatiramer acetate 20 mg subcutaneous injections in relapsing- remitting multiple sclerosis", MULTIPLE SCLEROSIS, vol. 14, September 2008 (2008-09-01), pages S296, XP009161078
		GAGNON L.: "Every-Other-Day Dosing of Glatiramer Acetate Reduces Adverse Reactions with Comparable Efficacy to Daily Dosing", WCTRMS, 21 September 2008 (2008-09-21), XP055508581 DOI: http://dx.doi.org/http://www.peervoice.com/every-other-day-dosing-glatiramer-acetate-reduces-adverse-reactions-comparable-efficacy-daily-dosing-presented-wctrms#
		BEJAOUI K. ET AL.: "There is no rebound worsening of multiple sclero- sis after stopping disease-modifying therapies", MULTIPLE SCLEROSIS, vol. 14, 2008, pages S31 - S32, XP055508582
		FLECHTER ET AL.: "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", J NEUROL SCI, vol. 197, 15 May 2002 (2002-05-15), pages 51 - 55, XP002679780 DOI: http://dx.doi.org/10.1016/S0022-510X(02)00047-3
		FLECHTER ET AL.: "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration", CLIN NEUROPHARM, vol. 25, no. 1, 2002, pages 11 - 15, XP009161076 DOI: http://dx.doi.org/10.1097/00002826-200201000-00002
		KHAN ET AL.: "P902 Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every - other - day glatiramer acetate 20 mg subcutaneous injections in relapsing -remitting multiple sclerosis", MULTIPLE SCLEROSIS, vol. 14, 2008, pages S296
		CAON ET AL.: "P06.141 Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", NEUROLOGY, vol. 72, no. 11, 17 March 2009 (2009-03-17), pages A317, XP009161100
		COHEN ET AL.: "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS", NEUROLOGY, vol. 68, no. 12, 2007, pages 939 - 944, XP002679784 DOI: http://dx.doi.org/10.1212/01.wnl.0000257109.61671.06
		SIMPSON ET AL.: "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis", CNS DRUGS, 2002, pages 925 - 850, XP009161077 DOI: http://dx.doi.org/10.2165/00023210-200216120-00004
		"Teva to Present Positive Data for Glatiramer Acetate 40 mg/1 ml Given Three Times Weekly for Relapsing-Remitting MS", 10 October 2012 (2012-10-10), XP055607303, Retrieved from the Internet
		KHAN ET AL.: "A phase 3 trial to assess the efficacy and safety of glatiramer acetate injections 40mg administered 3 times a week compared to placebo", 28TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS, 10 October 2012 (2012-10-10), XP055607318
		"Copaxone 20mg/ml, Solution For Injection, Pre-Filled Syringe", pages 1 - 7, XP055579983, Retrieved from the Internet
		"(P01.124) Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial", vol. 11, no. 3, suppl, 28 April 2009 (2009-04-28), 61st Annual Meeting of American-Academy-of-Neurology; Seattle, WA, USA, April 28 - 29, 2009, XP002743818, Retrieved from the Internet
		GIANCARLO COMI: "Results from a phase III, one-year randomized, double-blind, parallel-group, dose-comparison study with glatiramer acetate in relapsing-remitting multiple sclerosis", 2008, XP055607341, Retrieved from the Internet
		"Teva initiates phase III study to confirm increased efficacy of higher dose of Glatiramer Acetate for the treatment of relapsing-remitting Multiple Sclerosi", TEVA PRESS RELEASES, 2006, XP055581348, Retrieved from the Internet
		"Data Publised In Neurology Showed That Higher Dose Of Copaxone(R) increased Efficacy in Relapsing-Remitting Multiple Sclerosis (Rrms)", XP055607348, Retrieved from the Internet
		ALISON PALKHIVALA: "Doubling the Dose of Glatiramer Acetate Does Not Increase Efficacy", MEDSCAPE, 22 September 2008 (2008-09-22), XP055579985, Retrieved from the Internet
		"View of NCT01067521", CLINICALTRIALS.GOV ARCHIVE, 10 February 2010 (2010-02-10), XP055508500
		"Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006)", EXPERT REV. PHARMACOECONOMICS OUTCOMES RES., vol. 7, no. 2, 2007, pages 187 - 202, XP055579988 DOI: http://dx.doi.org/10.1586/14737167.7.2.187
		COSTELLO ET AL.: "Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term", MEDSCAPE J MED., vol. 10, no. 9, 30 September 2008 (2008-09-30), XP055579991, Retrieved from the Internet
		"Product Life-Cycle Management for Injectable Drugs: A Good Outlook for Proactive", 2 December 2006 (2006-12-02), XP055579996, Retrieved from the Internet [retrieved on 20160115]
		M. ROVARIS ET AL.: "Results of a randomised, double-blind, parallel-group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI-measured disease activity in relapsing-remitting multiple sclerosis", MULTIPLE SCLEROSIS, vol. 12, no. 1, 31 May 2006 (2006-05-31), pages 585, XP009157336
		DEVONSHIRE ET AL.: "P316 The Global Adherence Project - A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing- remitting multiple sclerosis", MULT. SCLER., vol. SI, December 2006 (2006-12-01), XP055579999
		"Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers", JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY, vol. 42, no. 2S, 1988, pages S1 - S26, XP055253757
		MULTIPLE SCLEROSIS, vol. 15, 2009, pages S249 - S250
		FLECHTER ET AL.: "Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: An open-label 2-year follow-up", J NEUROL SCI, vol. 197, no. 1-2, 15 May 2002 (2002-05-15), pages 51 - 55, XP002679780 DOI: http://dx.doi.org/10.1016/S0022-510X(02)00047-3
		FLECHTER ET AL.: "Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: Open multicenter study of alternate-day administration", CLIN NEUROPHARM, vol. 25, no. 1, 2002, pages 11 - 15, XP009161076 DOI: http://dx.doi.org/10.1097/00002826-200201000-00002
		KHAN ET AL.: "P902 Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every - other - day glatiramer acetate 20 mg subcutaneous injections in relapsing -remitting multiple sclerosis", MULTIPLE SCLEROSIS, vol. 14, 2008, pages S296, XP009161078
		CAON ET AL.: "P06.141 Randomized, Prospective, Rater-Blinded, Four Year Pilot Study To Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in RRMS", NEUROLOGY, vol. 72, no. 11, 17 March 2009 (2009-03-17), pages 3, XP009161100
		COHEN ET AL.: "Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS", NEUROLOGY, vol. 68, no. 12, 2007, pages 939 - 944, XP002679784 DOI: http://dx.doi.org/10.1212/01.wnl.0000257109.61671.06
		SIMPSON ET AL.: "Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis", CNS D, 2002, pages 825 - 850, XP009161077 DOI: http://dx.doi.org/10.2165/00023210-200216120-00004
		"Teva to Present Positive Data for Glatiramer Acetate 40 mg/1 ml Given Three Times Weekly for Relapsing-Remitting MS", TEVA PRESS RELEASE, 10 October 2012 (2012-10-10), XP055607303, Retrieved from the Internet
		KHAN ET AL.: "A phase 3 trial to assess the efficacy and safety of glatiramer acetate injections 40mg administered 3 times a week compared to placebo", ABSTRACT PRESENTED AT 28TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS, 10 October 2012 (2012-10-10), XP055607318
		"Copaxone 20mg/ml, Solution For Injection, Pre-Filled Syringe", COPAXONE UK PRODUCT LABEL ;, 17 April 2009 (2009-04-17), pages 1 - 7, XP055579983
		"(P01.124) Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial", NEUROLOGY; 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA, APRIL 28 - 29, 2009,, vol. 72, 28 April 2009 (2009-04-28), XP002743818
		"Results from a phase III, one-year randomized, double-blind, parallel-group, dose-comparison study with glatiramer acetate in relapsing-re", WORLD CONGRESS ON TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS, 2008, XP055607341
		"Teva initiates phase III study to confirm increased efficacy of higher dose of Glatiramer Acetate for the treatment of relapsing-remitting Multiple Sclerosis", TEVA PRESS RELEASES, 2006, XP055581348
		"Data Published in Neurology showed that higher dosie of Copaxone(R) increased efficacy in relapsing remitting Mutiple Sclerosis (Rrms)", 17 April 2007 (2007-04-17), XP055581344, Retrieved from the Internet
		"Doubling the Dose of Glatiramer Acetate Does Not Increase Efficacy", MEDSCAPE, 22 September 2008 (2008-09-22), XP055579985
		"View of NCT01067521", CLINICALTRIALS.GOV ARCHIVE, 10 February 2010 (2010-02-10), XP055508500
		SHI ET AL.: "mpact of dose frequency on compliance and health outcomes: a literature review (1966-2006)", EXPERT REV. PHARMACOECONOMICS OUTCOMES RES., vol. 7, no. 2, 2007, pages 187 - 202, XP055579988 DOI: http://dx.doi.org/10.1586/14737167.7.2.187
		COSTELLO ET AL.: "Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term", MEDSCAPE J MED., vol. 10, no. 9, 30 September 2008 (2008-09-30), pages 225, XP055579991
		"Product Life-Cycle Management for Injectable Drugs: A Good Outlook for Proactive Market players", 2 December 2006 (2006-12-02), XP055579996, Retrieved from the Internet
		M. ROVARIS ET AL.: "Results of a randomised, double-blind, parallel-group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI-measured disease activity in relapsing-remitting multiple sclerosis", MULTIPLE SCLEROSIS, vol. 12, no. Suppl. 1, 31 May 2006 (2006-05-31), pages 585, XP009157336
		DEVONSHIRE ET AL.: "P316 The Global Adherence Project - A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis", MULT. SCLER., vol. 12, no. S1, 2006, pages S82, XP055579999
		"Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers", JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY, vol. 42, no. 2S, 1988, pages S1 - S26, XP055253757
		NATIONAL LITIGATION REFERRED TO IN SECTION 1.2(C) ABOVE, GERMAN NULLITY CLAIM
	MULTIPLE SCLEROSIS, vol. 15, 2009, pages S249 - S250

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.